Lant Medical

Executive Summary

Lant Medical is a UK-based medical technology company founded in 2017, focused on developing innovative solutions for drug delivery and medical devices. Its lead product, HELIX, is a novel therapeutic targeting Helicobacter pylori infections, a widespread bacterial infection linked to peptic ulcers and gastric cancer. The company aims to address the growing challenge of antibiotic resistance and the inadequacy of current therapies by offering an over-the-counter and prescription treatment option. HELIX leverages a unique mechanism that could potentially reduce treatment duration and improve patient compliance, addressing a significant unmet need in the global gastrointestinal market. Despite its promising approach, Lant Medical operates at an early stage with limited public information on funding, clinical progress, or regulatory milestones. The company faces strong competition from established antibiotic regimens and emerging microbiome-based therapies. However, the increasing prevalence of antibiotic-resistant H. pylori strains and the demand for non-antibiotic alternatives create a favorable market opportunity. Lant Medical's ability to secure partnerships or advance HELIX into clinical trials will be critical for its success. The company's lean profile and UK base suggest potential for cost-effective development and access to European markets.

Upcoming Catalysts (preview)

• Q3 2026Initiation of phase 1 clinical trial for HELIX40% success
• Q4 2026Partnership or licensing agreement for HELIX50% success
• Q1 2027Regulatory designation (e.g., FDA fast track or orphan drug) for HELIX30% success